Advisory Services Network’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-42
| Closed | -$8.38K | – | 3571 |
|
|
2026
Q1 | $8.38K | Buy |
+42
| New | +$8.31K | ﹤0.01% | 3646 |
|
|
2025
Q4 | – | Sell |
-10
| Closed | -$1.77K | – | 3224 |
|
|
2025
Q3 | $1.77K | Buy |
+10
| New | +$1.49K | ﹤0.01% | 3826 |
|
|
2024
Q1 | – | Sell |
-112
| Closed | -$8K | – | 2700 |
|
|
2023
Q4 | $8K | Buy |
+112
| New | +$6.61K | ﹤0.01% | 2953 |
|
|
2023
Q2 | – | Sell |
-119
| Closed | -$8.75K | – | 2678 |
|
|
2023
Q1 | $8.75K | Buy |
119
+7
| +6% | +$498 | ﹤0.01% | 2933 |
|
|
2022
Q4 | $7.48K | Buy |
+112
| New | +$7.28K | ﹤0.01% | 2965 |
|
|
2021
Q3 | – | Sell |
-180
| Closed | -$15K | – | 2446 |
|
|
2021
Q2 | $15K | Buy |
+180
| New | +$15K | ﹤0.01% | 2625 |
|
|
2021
Q1 | – | Sell |
-260
| Closed | -$16K | – | 2250 |
|
|
2020
Q4 | $16K | Sell |
260
-3
| -1% | -$171 | ﹤0.01% | 2225 |
|
|
2020
Q3 | $15K | Buy |
+263
| New | +$17.9K | ﹤0.01% | 2215 |
|
|
2020
Q2 | – | Sell |
-340
| Closed | -$15K | – | 2003 |
|
|
2020
Q1 | $15K | Sell |
340
-123
| -27% | -$6.97K | ﹤0.01% | 2033 |
|
|
2019
Q4 | $30K | Sell |
463
-119
| -20% | -$7.95K | ﹤0.01% | 1794 |
|
|
2019
Q3 | $41K | Hold |
582
| – | – | ﹤0.01% | 1459 |
|
|
2019
Q2 | $41K | Sell |
582
-333
| -36% | -$24.5K | ﹤0.01% | 1457 |
|
|
2019
Q1 | $72K | Sell |
915
-18
| -2% | -$1.36K | 0.01% | 1103 |
|
|
2018
Q4 | $79K | Buy |
933
+11
| +1% | +$1.17K | 0.01% | 983 |
|
|
2018
Q3 | $158K | Sell |
922
-37
| -4% | -$5.58K | 0.01% | 824 |
|
|
2018
Q2 | $139K | Sell |
959
-3
| -0.3% | -$335 | 0.01% | 833 |
|
|
2018
Q1 | $99K | Buy |
962
+15
| +2% | +$1.48K | 0.01% | 1022 |
|
|
2017
Q4 | $81K | Buy |
947
+721
| +319% | +$62.5K | 0.01% | 1058 |
|
|
2017
Q3 | $19K | Hold |
226
| – | – | ﹤0.01% | 1420 |
|
|
2017
Q2 | $17K | Buy |
226
+29
| +15% | +$2.03K | ﹤0.01% | 1398 |
|
|
2017
Q1 | $13K | Buy |
+197
| New | +$13K | ﹤0.01% | 1378 |
|
|
2016
Q3 | $11K | Hold |
180
| – | – | ﹤0.01% | 1281 |
|
|
2016
Q2 | $13K | Hold |
180
| – | – | ﹤0.01% | 1130 |
|
|
2016
Q1 | $12K | Buy |
+180
| New | +$10.9K | ﹤0.01% | 1024 |
|
Other funds holding LGND
JT
CAM
Advisory Services Network's LGND Position: Q2 2026 in Review
Advisory Services Network sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 42 shares — an estimated $8.38K sold.
Advisory Services Network first reported a position in LGND in Q1 2016 and held it in 24 quarters. The position peaked at $158K in Q3 2018. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Advisory Services Network reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Advisory Services Network sold 42 Ligand Pharmaceuticals shares in Q2 2026, an estimated $8.38K.
- Advisory Services Network first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 24 quarters.
- Advisory Services Network's Ligand Pharmaceuticals position peaked at $158K in Q3 2018.
- 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.